9 results about "Companion diagnostic" patented technology

The application provides application of serum sIL-2R as an ADAM10 inhibitor companion diagnostic marker and a corresponding kit, including two core application scenarios: before treatment, screening of a patient population with high activity of an ADAM10-sIL-2R pathway and most likely to benefit from ADAM10 inhibitor treatment by detecting the serum sIL-2R level of the patient; during and after treatment, evaluating the inhibition effect of the ADAM10 inhibitor on the target pathway and the treatment efficacy by dynamically monitoring the change of the serum sIL-2R level; the liquid companion diagnostic strategy will provide an indispensable supporting tool for the precise application of the ADAM10 inhibitor in pancreatic cancer, and significantly improve the precision and effectiveness of clinical medication.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

The invention relates to the field of gene therapy. In addition the invention relates to the field of interfering RNA and / or microRNA (miRNA). In particular the invention relates to gene therapy involving such miRNA's and more in particular to diagnostic tools to be implemented in the treatment of disease, when such treatment is carried out by delivery of miRNA's to a patient, i.e. to cells of a patient. The present invention uses the content of extracellular vesicles that are found in body fluids to determine the presence of miRNA's or the like expressed through the introduction of a gene delivery vehicle is in a host.

This invention discloses a hexavanadate-bridged double-ended click nucleic acid probe construct, its preparation method, and its application, relating to the field of bioanalytical technology. The hexavanadate-bridged double-ended click nucleic acid probe construct comprises a hexavanadate derivative V6-(N3)2 bridging scaffold with azido groups at both ends, and two identical oligonucleotides MB1 or MB2; MB1 is terminally alkyne and labeled with a FAM fluorescent group, and MB2 is terminally alkyne and labeled with a Cy5 fluorescent group; V6-(N3)2 and MB1 or MB2 undergo a Cu(I)-catalyzed azido-alkynyl cycloaddition reaction to form a 1,2,3-triazole linker bond, connecting to form an MB1-triazole-V6-triazole-MB1 or MB2-triazole-V6-triazole-MB2 structure. This invention also discloses a method for preparing this construct, wherein the finished product is obtained through a click reaction in an aqueous buffer system, copper removal and desalting, and separation and purification. And its application in nucleic acid sequence-specific detection, with its fluorescence quantitative readout mechanism, improves the robustness of sequence identification, mismatch detection and quantitative detection, and is suitable for pathogen identification, gene mutation screening, molecular diagnostics and drug companion diagnostics.

This invention provides the application of CPXM2 targeting in the treatment of pancreatic cancer. Specifically, this invention provides the use of a CPXM2 inhibitor in the preparation of compositions or formulations for: (a) the prevention and / or treatment of pancreatic cancer; and / or (b) the inhibition of the growth of pancreatic cancer cells or pancreatic cancer tissue. This invention also provides the use of the CPXM2 target in pancreatic cancer subtyping, corresponding companion diagnostic product combinations, and pharmaceutical compositions for synergistic treatment of pancreatic cancer. This invention provides a new and effective approach to improve the efficacy of pancreatic cancer treatment, which currently lacks satisfactory results, and has broad prospects.

Disclosed are engineered cells and anti-CD19 CAR-expressing engineered immune cells having inactivated immune checkpoint genes and armoring modifications, including the engineered HLA Class I expression and inhibition of native HLA Class II expression, as well as therapeutic compositions including the cells, therapeutic methods including administration of the cells, and companion diagnostic methods for the therapeutic compositions.

The present invention relates to an immunoreactive molecule that specifically recognises and binds to human Ankyrin Repeat Domain-Containing Protein 30A (NY-BR-1) and, in particular, to an immunoreactive molecule, which shows no cross-reactivity to other human Ankyrin repeat domain containing proteins. The invention further relates to the use of such immunoreactive molecules in the treatment of cancer as well as in companion diagnostics methods.

This invention is in the field of medicine. More particularly the invention is in the field of treating sepsis and related disorders, and disorder wherein certain cytokines are elevated. The invention further relates to treating diseases where cytokines need to be suppressed. Further described is a companion diagnostic test.